{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:36:09Z","timestamp":1791549369712,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.metop.2026.100479","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:54:12Z","timestamp":1779260052000},"page":"100479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["What's in a name? From PCOS to polyendocrine metabolic ovarian syndrome: A metabolic reframing, promise, controversies, and challenges ahead"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-388X","authenticated-orcid":false,"given":"Maria","family":"Dalamaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.metop.2026.100479_bib1","first-page":"717","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"S0140\u20136736","author":"Teede","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2026.100479_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103287","article-title":"Polycystic ovary syndrome perspectives from patients and health professionals on clinical features, current name, and renaming: a longitudinal international online survey","volume":"84","author":"Teede","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.metop.2026.100479_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/humupd\/dmaf030","article-title":"Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis","volume":"32","author":"Neven","year":"2026","journal-title":"Hum Reprod Update"},{"issue":"9","key":"10.1016\/j.metop.2026.100479_bib4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome","volume":"10","author":"Joham","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.metop.2026.100479_bib5","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metop.2026.100479_bib6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 International Evidence-based Guideline for the assessment and management of polycystic ovary syndrome","volume":"120","author":"Teede","year":"2023","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.metop.2026.100479_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3682","article-title":"Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome","volume":"39","author":"Lempesis","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.metop.2026.100479_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"CLINICAL PRACTICE. Polycystic ovary syndrome","volume":"375","author":"McCartney","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metop.2026.100479_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.fertnstert.2022.03.009","article-title":"Polycystic ovary syndrome: a \"risk-enhancing\" factor for cardiovascular disease","volume":"117","author":"Guan","year":"2022","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.metop.2026.100479_bib10","doi-asserted-by":"crossref","DOI":"10.1530\/REP-25-0102","article-title":"Polycystic ovary syndrome: origins and implications: polycystic ovary syndrome: the impact of androgen excess on metabolic health","volume":"170","author":"Cussen","year":"2025","journal-title":"Reproduction"},{"issue":"6","key":"10.1016\/j.metop.2026.100479_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2013.09.014","article-title":"Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study","volume":"69","author":"Dalamaga","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.metop.2026.100479_bib12","doi-asserted-by":"crossref","first-page":"e2298","DOI":"10.1210\/clinem\/dgae910","article-title":"Approach to the patient: diagnostic challenges in the workup for polycystic ovary syndrome","volume":"110","author":"Joham","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.metop.2026.100479_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S2352-4642(24)00019-1","article-title":"Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood","volume":"8","author":"Simon","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"5 Pt 2","key":"10.1016\/j.metop.2026.100479_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.fertnstert.2025.09.006","article-title":"Update on diagnosis of polycystic ovary syndrome during adolescence","volume":"124","author":"Pe\u00f1a","year":"2025","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metop.2026.100479_bib15","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag198","article-title":"Approach to the diagnosis and treatment of polycystic ovarian syndrome in adolescent patients","author":"Machado","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metop.2026.100479_bib16","doi-asserted-by":"crossref","first-page":"e2407","DOI":"10.1210\/clinem\/dgaf094","article-title":"NAFLD vs MASLD (Metabolic dysfunction-associated steatotic liver Disease)-Why the need for a change of nomenclature?","volume":"110","author":"Gastaldelli","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metop.2026.100479_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s13679-026-00713-8","article-title":"Metabolic dysfunction-associated steatotic liver disease and respiratory disorders: a systematic review of clinical and pathophysiological associations","volume":"15","author":"Georgakopoulou","year":"2026","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.metop.2026.100479_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100410","article-title":"Liver transplantation in the era of obesity: a metabolic public health crisis meets a surgical frontier","volume":"28","author":"Rozani","year":"2025","journal-title":"Metabol Open"},{"issue":"7","key":"10.1016\/j.metop.2026.100479_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/metabo14070366","article-title":"NAFLD\/MASLD and the gut-liver axis: from pathogenesis to treatment options","volume":"14","author":"Vallianou","year":"2024","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.metop.2026.100479_bib20","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metop.2026.100479_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.metop.2026.100479_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.17846","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Loomba","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.metop.2026.100479_bib23","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1001\/jama.2025.20467","article-title":"MASLD-The chronic liver disease that affects tens of millions of US adults but flies under the radar","volume":"334","author":"Rubin","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.metop.2026.100479_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.fertnstert.2018.09.013","article-title":"Metabolic disturbances in Non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"111","author":"Zhu","year":"2019","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.metop.2026.100479_bib25","doi-asserted-by":"crossref","first-page":"e1364","DOI":"10.1210\/clinem\/dgaf606","article-title":"Adolescent \"Lean PCOS\" is characterized by higher insulin resistance and adverse adipokine profile","volume":"111","author":"Whooten","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metop.2026.100479_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/cen.15302","article-title":"Nonobese PCOS compared to obese PCOS have similar clinical presentation, hormonal profile, and insulin resistance","volume":"103","author":"Patwari","year":"2025","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.metop.2026.100479_bib27","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1210\/jc.2013-2040","article-title":"Renaming PCOS--a two-state solution","volume":"98","author":"Dunaif","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.metop.2026.100479_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.fertnstert.2011.09.024","article-title":"Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE\/ASRM-Sponsored 3rd PCOS Consensus Workshop Group","volume":"97","author":"Fauser","year":"2012","journal-title":"Fertil Steril"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:18:15Z","timestamp":1781209095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936826000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S2589936826000381"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2026.100479","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What's in a name? From PCOS to polyendocrine metabolic ovarian syndrome: A metabolic reframing, promise, controversies, and challenges ahead","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2026.100479","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100479"}}